Radium Incorporated products

Vial infusion of radioisotopes in Theranostics requires shielding the nuclear medicine technologist administering a dose. ClearView Vial Shield can be used for Ac-225 PSMA, I-123 and I-131 mIBG therapies, Lutathera (Lu-177) therapies for Neuroendocrine Tumor Treatment, FDA approved Pluvicto^TM (lutetium Lu 177 vipivotide tetraxetan or 177Lu-PSMA-617) for the treatment of prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC). Using lead vial shields has led to incomplete infusion of radionuclides such as Lu-177 which is used to treat Neuroendocrine Tumors and PSMA Therapies.The ClearView Vial Shield provides significant workflow and operational advantages over available products. Lead vial shields are heavy to handle, and being RoHS restricted substance requiring special handling.

The ClearView Beta-Gamma Syringe Shield is constructed of polycarbonate and acrylic materials which shields against Beta emission and errant bremsstrahlung, and the tungsten based ClearView solution inside attenuates gamma’s. A single syringe shield works with 10cc and 20cc syringes. A thumbscrew holds the syringe firmly in place.

ClearView Radiation Shielding syringe or injection pump shield is designed to reduce exposure the nuclear medicine technologist. The ClearView Infusion Pump Shield fits most infusion pumps such as Grasbey, Medifusion, Moog Curlin, etc. is being used in Theranostics centers for infusion of radiopharmaceuticals such as Lutathera, Azedra, AdreView, Megatope, HICON™. The ClearView Infusion Pump Shield works for infusion treatments from Ac-225 PSMA, I-123 and I-131 mIBG therapies, Lutathera (Lu-177) therapies for Neuroendocrine Tumor Treatment, FDA approved PluvictoTM (lutetium Lu 177 vipivotide tetraxetan or 177Lu-PSMA-617) for the treatment of prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC).

Designed to place a foley bag connected to a catheter attached to patients undergoing radiotherapy and scans using radiopharmaceuticals over performed by nuclear medicine specialists or radiologists. The see-through container reduces exposure to hospital staff as the see-through feature of ClearView allows to monitor the level of the foley bags without needing to manually handle radioactive urine. ClearView provides a significant shift from using lead-based waste containers where monitoring urine volume in the foley bag, proper functioning of the pump and inspection of leaks leads in a much higher exposure to the hospital staff.

The ClearView Rolling Shield is a mobile rolling shield available in lead equivalency up to 1’’ Pb.Eq. and is being used in several Theranostics suites and radiotherapies such as Ac-225 PSMA, I-123 and I-131 mIBG therapies, Lutathera (Lu-177) therapies for Neuroendocrine Tumor Treatment, FDA approved Pluvicto^TM (lutetium Lu 177 vipivotide tetraxetan or 177Lu-PSMA-617) for the treatment of prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC). Procedures such as pediatric mIBG Radiotherapy which treats Neuroblastoma (solid tumor) in young children as young as 3 years, use I131 between 250 mCi and 1200 mCi.